Abstract
Acute myeloid leukemias (AML) comprising approximately 15 % of pediatric leukemias account for 30 % of all leukemic deaths in children worldwide. The 5-year overall survival (OS) rate now reaches 60–65 % in Western Europe, North America, and the developed countries of Australasia due to risk-tailored chemotherapy and vigorous supportive care. According to data of the Childhood Cancer Registry of the Hungarian Pediatric Oncology-Hematology Group (HPOG), 234 children with AML were treated using the AML-IGCI-90, the AML-BFM-93 (1990–2000), and the AML-BFM-98 (2001–2011) protocols in Hungary. Four-year OS of patients was 34.5 % with the IGCI-90 and 47.9 % with the BFM-98 protocol. Mortality in AML is mainly associated with progressive disease; however, 5–15 % of patients die from treatment-related complications. We have retrospectively analyzed in detail the causes of death in a cohort of patients diagnosed between 2001 and 2011. There were 59 of 112 (52.6 %) fatal events registered until December 31, 2011. The main causes of deaths were progressive disease in 28 patients (47.4 %), infection in 21 patients (35.5 %), bleeding in 6 patients (10.4 %). Hematopoietic stem cell transplantation (HSCT) was carried out in 30 patients and there were 12 (12/59; 20.3 %) transplantation-related deaths of that transplantation-related graft-versus-host disease (GVHD) was seen in 3 patients (5.0 %). Second malignancy (a medulloblastoma) in 1 patient (1.7 %) occurred. HPOG follows the advanced diagnostic and treatment methods of the International BFM Study Group (I-BFM-SG). Unfortunately, treatment outcome measures do not reach that of working groups participating in I-BFM-SG AML clinical trials. The key for improving cure rates in Hungary is to decrease treatment-related mortality (TRM) by applying more vigorous supportive care for children with AML preferably within the frames of clinical studies.
Similar content being viewed by others
References
Riley LC, Hann IM, Wheatley K, et al. Treatment-related deaths during induction and first remission of acute myeloid leukemia in children treated on the Tenth Medical Research Council Acute Myeloid Leukemia Trial (MRC AML10). Br J Haematol. 1999;106:436–44.
Kaspers GJL, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92:1519–32.
Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384–93.
Mollgaard-Hansen L, Möttönen M, Glosli H, et al. Early and treatment related deaths in childhood acute myeloid leukemia in the Nordic countries: 1984–2003. Br J Haematol. 2010;151:447–59.
Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;119:5980–8.
Creutzig U, Reinhardt D, Zimmermann M, AML-BFM Study-Group. Prognostic relevance of risk groups in the pediatric AML-BFM trials 93 and 98. Ann Hematol. 2004;83(Suppl 1):112–6.
Creutzig U, Büchner T, Sauerland MC, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008;112:562–71.
Fink FM, Gadner H, Grümayer ER, et al. Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian-Hungarian study AML-IGCI-84. Haematol Blood Transfus. 1990;33:233–6.
Jeha S. Who should be treating adolescents and young adults with acute lymphoblastic leukaemia? Eur J Cancer. 2003;39:2579–83.
Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA. 2004;291:2471–5.
Kiss C, Jakab Z, Bakos-Tóth M, Bartyik K, et al. Complex care of children with cancer in Hungary (In Hungarian, English abstract). Gyermekgyógyászat. 2008;59:137–42.
Conflict of interest
The authors declare that there is no actual or potential conflict of interest in relation to this article.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
I. Szegedi and Z. Jakab are equal opportunity first authors.
Rights and permissions
About this article
Cite this article
Szegedi, I., Jakab, Z., Masát, P. et al. Development of treatment and clinical results in childhood acute myeloid leukemias in Hungary. memo 6, 69–72 (2013). https://doi.org/10.1007/s12254-012-0054-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-012-0054-8